You are here: membersIMARC ServicesBlog

Hyperlipidemia Drugs Market Size, Share, Growth and Forecast 2023-2028

The latest report by IMARC Group, titled “Hyperlipidemia Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“. The global hyperlipidemia drugs market size reached US$ 22.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 25.2 Billion by 2028, exhibiting a growth rate (CAGR) of 1.8% during 2023-2028.

Hyperlipidemia drugs, also known as lipid-lowering medications, are a class of pharmaceuticals designed to manage and regulate abnormal levels of lipids, including cholesterol and triglycerides, in the bloodstream. These drugs play a crucial role in the prevention and treatment of cardiovascular diseases, which can result from the accumulation of excess lipids in the arteries. One of the most common type of hyperlipidemia drug is statins, which functions by inhibiting the enzyme responsible for cholesterol production in the liver. Statins are widely prescribed due to their proven effectiveness in lowering LDL (low-density lipoprotein) cholesterol, also known as “bad” cholesterol. Another class of medications includes bile acid sequestrants, which bind to bile acids in the intestine, reducing cholesterol absorption. Fibrates, on the other hand, primarily target triglyceride levels, making them suitable for individuals with elevated triglycerides.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/hyperlipidemia-drugs-market/requestsample

Hyperlipidemia Drugs Market Trends and Drivers:

The rising prevalence of cardiovascular diseases, including heart attacks and strokes, is a significant driver for the hyperlipidemia drugs market. Hyperlipidemia is a major risk factor for these conditions, necessitating the use of lipid-lowering medications to manage cholesterol levels and reduce the risk of heart-related events. Additionally, the global population is aging, and older individuals are more susceptible to hyperlipidemia. As individuals age, their cholesterol levels tend to rise, increasing the demand for hyperlipidemia drugs to maintain cardiovascular health. Other than this, sedentary lifestyles, poor dietary habits, and high consumption of processed foods contribute to elevated cholesterol levels. These lifestyle factors have become more prevalent, especially in urban areas, leading to a greater need for hyperlipidemia drugs. Besides this, public awareness about the importance of managing cholesterol and its impact on heart health has increased. This heightened awareness drives individuals to seek medical advice and, if necessary, lipid-lowering medications. In line with this, improved healthcare infrastructure in emerging economies allows for better diagnosis and management of hyperlipidemia. This, in turn, contributes to the growth of the hyperlipidemia drugs market. Moreover, pharmaceutical companies continue to invest in research and development, leading to the discovery of newer and more effective hyperlipidemia drugs. Innovations in drug formulation and delivery systems provide healthcare providers with a wider range of treatment options.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Drug Type:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • PCSK9 Inhibitors
  • Others

Breakup by End User:

  • Hospitals
  • Clinics
  • Others

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape with Key Player:

  • Amgen Inc.
  • AstraZeneca PLC
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Esperion Therapeutics Inc.
  • GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
  • Immuron Limited
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi S.A.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal

  1. Hyperlipidemia Drugs Market
  2. Hyperlipidemia Drugs Market Share
  3. hyperlipidemia drugs market size

Comments on this entry

There are no comments at this time.

Add a comment

Please keep comments relevant to this entry.

Line breaks and paragraphs are automatically converted. URLs (starting with http://) or email addresses will automatically be linked.